Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 8;15(1):216.
doi: 10.1186/s12916-017-0978-2.

The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases

Affiliations

The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases

Sébastien Cortaredona et al. BMC Med. .

Abstract

Background: The literature offers competing estimates of disease costs, with each study having its own data and methods. In 2007, the Dutch Center for Public Health Forecasting of the National Institute for Public Health and the Environment provided guidelines that can be used to set up cost-of-illness (COI) studies, emphasising that most COI analyses have trouble accounting for comorbidity in their cost estimations. When a patient has more than one chronic condition, the conditions may interact such that the patient's healthcare costs are greater than the sum of the costs for the individual diseases. The main objective of this work was to estimate the costs of 10 non-communicable diseases when their co-occurrence is acknowledged and properly assessed.

Methods: The French Echantillon Généraliste de Bénéficiaires (EGB) database was used to assign all healthcare expenses for a representative sample of the population covered by the National Health Insurance. COIs were estimated in a bottom-up approach, through regressions on individuals' healthcare expenditure. Two-way interactions between the 10 chronic disease variables were included in the expenditure model to account for possible effect modification in the presence of comorbidity(ies).

Results: The costs of the 10 selected chronic diseases were substantially higher for individuals with comorbidity, demonstrating the pattern of super-additive costs in cases of diseases interaction. For instance, the cost associated with diabetes for people without comorbidity was estimated at 1776 €, whereas this was 2634 € for people with heart disease as a comorbidity. Overall, we detected 41 cases of super-additivity over 45 possible comorbidities. When simulating a preventive action on diabetes, our results showed that significant monetary savings could be achieved not only for diabetes itself, but also for the chronic diseases frequently associated with diabetes.

Conclusions: When comorbidity exists and where super-additivity is involved, a given preventive policy leads to greater monetary savings than the costs associated with the single diagnosis, meaning that the returns from the action are generally underestimated.

Keywords: Chronic diseases; Comorbidity; Cost of illness; Prevention policies.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was also approved by the French Commission on Individual Data Protection and Public Liberties (Commission Nationale Informatique et Libertés). Patient information was anonymised and de-identified prior to analysis.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Similar articles

Cited by

References

    1. Organisation for Economic Co-operation and Development. What Future for Health Spending? OECD Policy Notes. 2013. http://www.oecd.org/eco/growth/aaaaaawhatfuture.pdf. Accessed 1 July 2016.
    1. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy Amst Neth. 2006;77:51–63. doi: 10.1016/j.healthpol.2005.07.016. - DOI - PubMed
    1. Bloom BS, Bruno DJ, Maman DY, Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics. 2001;19:207–13. doi: 10.2165/00019053-200119020-00007. - DOI - PubMed
    1. Liu JLY, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart Br Card Soc. 2002;88:597–603. doi: 10.1136/heart.88.6.597. - DOI - PMC - PubMed
    1. Hogan P, Dall T, Nikolov P, American Diabetes Association Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917–32. doi: 10.2337/diacare.26.3.917. - DOI - PubMed

LinkOut - more resources